Drugs / BLEOMYCIN A6
BLEOMYCIN A6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01660399 | Aug 2012 → Nov 2016 | squamous cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLEOMYCIN A6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231529 ↗ |
| Known as | Boanmycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660399 ↗ |
| Known as | Pingyangmycin a6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231529 ↗ |
| Known as | Zhengguangmycin a6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231529 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1231529 ↗ |
| Route | Intramuscular | “Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.” NCT01660399 ↗ |
| Route | Intravenous | “Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.” NCT01660399 ↗ |